Entasis Therapeutics Holdings Inc.

ETTXCIK 0001724344 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 2, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0013

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Entasis Therapeutics Holdings Inc.

Name	Roles	Filings
Altarac David	Officer	2
Berger Heather A.	Director	2
Gutch Michael	Officer	2
Hastings David C	Director	2
Keiley Elizabeth M	Officer	2

Showing 1-5 of 15

Per pagePage 1 of 3Next

All filings

25 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Feb 25, 2022	Wagner Kristie Ann VP, Principal Fin & Acct Off	AGrant	10,000	$0.00	$0
Feb 23, 2022	Innoviva, Inc. 10% Owner	Holdings only	-	-	-
Feb 15, 2022	Keiley Elizabeth M General Counsel	Holdings only	-	-	-
Feb 15, 2022	Hastings David C Director	Holdings only	-	-	-
Feb 15, 2022	Altarac David Chief Medical Officer	Holdings only	-	-	-

Showing 1-5 of 25

Per pagePage 1 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value

Entasis Therapeutics Holdings Inc.

Annual report (10-K)

Top insiders

All filings

External resources

Permalink